IN THE HIGH COURT OF NEW ZEALAND AUCKLAND REGISTRY
I TE KŌTI MATUA O AOTEAROA TĀMAKI MAKAURAU ROHE
CIV-2016-404-3299
[2018] NZHC 208
BETWEEN LESLIE NORMAN AUSTIN
Plaintiff
AND
ROCHE PRODUCTS (NEW ZEALAND) LIMITED
First Defendant
F. HOFFMANN-LA ROCHE AG Second Defendant
ROCHE
Third Defendant
Hearing: 20 February 2018 Appearances:
G J Thwaite for Plaintiff/Respondent
J A MacGillivray / S M Jass for First Defendant/Applicant
Judgment:
21 February 2018
JUDGMENT OF AJ CHRISTIANSEN
This judgment was delivered by me on
21.02.18 at 4.00 p.m. pursuant to Rule 11.5 of the High Court Rules.
Registrar/Deputy Registrar Date ……………
AUSTIN v ROCHE PRODUCTS (NEW ZEALAND) LIMITED & ORS [2018] NZHC 208 [21 February 2018]
[1] The first defendant’s strike out application addresses the pleading of the plaintiff’s second amended statement of claim filed on 22 February 2017. It appears the second defendant has not been served with the proceeding and it is unclear whether the proceeding against the third defendant is to be pursued.
The pleading background
[2] The claim against the first defendant identifies a single cause of action. The claim in negligence seeks various heads of compensatory and exemplary damages.
[3] The first defendant is a New Zealand registered company that is apparently owned by a Swiss company and is a manufacturer and distributor of pharmaceutical products. For present purposes the defendants will be referred to as the “Roche Group”.
[4] In the 1950s the Roche Group developed Roaccutane for use in the treatment of acne. From about 1985 Roaccutane was distributed in New Zealand. Its primary use was for treatment of serious acne.
[5] It is pleaded that from 1983 a series of papers questioned the safety of Roaccutane linking long term use with skeletal abnormalities.
[6] In 1985 when he was 33 the plaintiff consulted a dermatologist about his acne and was prescribed Roaccutane. Further and under the medical guidance of two or more dermatologists the plaintiff used Roaccutane from 1985 to 2005.
[7] The plaintiff had been a keen and active golfer for many years and opened a business to supply products to golfers. From the early 1990’s the plaintiff alleges that his skill in golfing was being affected by his “physical condition” and that he had ongoing treatment of spinal issues including:
·Partially prolapsed disks in 1993;
·Stiff neck and back in 1997;
·Carpal bossing in 2000;
·Cervical problems in 2001;
·Surgery to left wrist in 2005;
·Osteophytosis in 2011;
·Thyroidectomy surgery in 2011;
·Dorsal osteophytosis in 2012;
·Intra-articular fluoroscopy in 2013;
·Lower limb neurogenic claudication and prominent anterior ossification in 2015;
·Cervical spinal injury in 2015;
·Lumbar spinal surgery in 2016.
[8] The plaintiff says on 23 February 2015 he was advised for the first time by his musculoskeletal specialist that his medical ailments were, or may be, linked to his use of Roaccutane.
[9] The plaintiff ceased his use of Roaccutane in 2005 having at that time used Roaccutane that was prescribed to his sons.
[10] On 29 March 2015 the plaintiff lodged a treatment…
Keep reading for free
Create a free CaseChat account to read Austin v Roche Products (New Zealand) Ltd and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2018] NZHC 208
- Decision Date
CaseChat Overview and Summary
The legal issues before the Court were whether the plaintiff’s claim was statute-barred under the Limitation Act 1950 and whether the claim for compensatory damages was barred by the Accident Compensation Act 2001. The Court had to determine whether the cause of action accrued when Austin first suffered injury or when he discovered the connection between his injuries and Roaccutane, and whether there was sufficient evidence of fraudulent concealment to extend the limitation period. The Court also needed to consider whether claims for compensatory damages were precluded by ACC coverage, while allowing for the possibility that the injuries might not fall within the scope of the ACC regime.
The Court found that the issues raised by Roche’s strike out application could not be properly decided without a full evidentiary hearing. The Court considered that the plaintiff's medical records and the published medical studies suggested that Austin could have discovered the connection between his injuries and Roaccutane earlier, but this required further evidence. The Court also noted that the plaintiff had received ACC coverage for his injuries, but this did not preclude the possibility that he could argue his injuries did not fall within the scope of the ACC regime. The Court concluded that the issues were complex and required detailed evidence to resolve, and thus dismissed Roche's application to strike out the claim. The Court ordered Roche to pay Austin’s costs on a 2B basis and directed Roche to file and serve a statement of defence within 20 working days, subject to any appeal against the judgment.
Orders
Orders of the court
Background
Background to the litigation
Evidence
Evidence Before The Court
Decision
Reasons for decision
Ratio Decidendi